Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Association Between Hospital Admissions and Healthcare Provider Communication for Individuals With Sickle Cell Disea...Objective: To test the hypothesis that ...
-
Vitamin D Supplements May Reduce Pain-related Emergency Room Visits in Children With SCDTaking vitamin D supplements may lower t...
-
Aflac Cancer and Blood Disorders Center of Children’s Healthcare of AtlantaAs one of the leading pediatric cancer, ...
-
Nationwide Children’s HospitalThe Comprehensive Sickle Cell and Thalas...
-
Jennifer A. Rothman, M.D.Dr. Rothman treats children with cancer ...
-
Susan Claster, MDDr. Claster graduated from the Universit...
-
Pfizer rare disease introduces Council for Change to further help SCD patientsFollowing a report earlier thi...
